
February 14, 2025
Study now recruiting patients to treat PANcreatic adenocarcinoma with Gemcitabine, Erlotinib, and nAb-paclitaxel (PANGEA)
UNC Lineberger has opened a two-arm clinical trial to determine the optimal combination treatment for patients with advanced unresectable or metastatic basal-like subtype pancreatic ductal adenocarcinoma.